Haemonetics earnings release, August 6, 2026
Haemonetics R eports First Quarter Fiscal 2027 Results;
Raises Total Company Fiscal 2027 Guidance
Boston,
MA, August 6, 2026
-
Haemonetics Corporation (NYSE: HAE) reported financial results for its first quarter of fiscal 2027, which ended June 27, 2026:
__________
(1)
Excludes the impacts of currency fluctuation and the exit of certain liquid solution products.
Chris Simon, Haemonetics’ CEO, stated: “We had a strong start to fiscal 2027, gaining Plasma share, sustaining Blood Management Technologies momentum, and returning Interventional Technologies to growth. With our evolved portfolio, transformed operating model and disciplined execution, we are strengthening our competitive position and demonstrating the durable growth of our diversified businesses. We raised full-year guidance, and Haemonetics is well-positioned to deliver sustainable long-term growth and shareholder value.”¹
GAAP RESULTS
First quarter fiscal 2027 revenue was $339.4 million, up 5.6% compared with the first quarter of fiscal 2026. Business unit revenue and growth rates compared with the prior year period were as follows:
Gross margin was 59.8% in the first quarter of fiscal 2027, which was relatively flat when compared with 59.8% in the first quarter of fiscal 2026. Operating expenses were $145.3 million, up $7.0 million, or 5.0%, compared with the first quarter of fiscal 2026. The increase in operating expenses was driven by higher personnel-related costs and freight charges. The Company had operating income of $57.5 million and a 16.9% operating margin in the first quarter of fiscal 2027, compared with operating income of $53.9 million and a 16.8% operating margin in the first quarter of fiscal 2026. The effective income tax rate was 30.6% in the first quarter of fiscal 2027, compared with 24.7% in the first quarter of fiscal 2026. The increase in the effective income tax rate was primarily driven by stock compensation shortfalls and valuation allowance impacts related to losses in certain recently acquired jurisdictions. First quarter fiscal 2027 net income and earnings per diluted share were $33.0 million and $0.72, respectively, compared with $34.0 million and $0.70, respectively, in the first quarter of fiscal 2026.
ADJUSTED RESULTS
First quarter organic revenue growth was
5.9% compared with the same period of fiscal 2026. Year-over-year organic revenue growth rates by business unit were as follows:
First quarter fiscal 2027 adjusted gross margin was 60.4%, down 40 basis points compared with the prior year period. The primary drivers of the decrease in the adjusted gross margin percentage included upfront revenue recognition upon the execution of a long-term software agreement in the prior year, partially offset by the continued transformation of the product portfolio to higher-margin offerings and benefits from product innovation.
Adjusted operating expenses were $125.6 million, up $7.9 million, or 6.7%, compared with the first quarter of fiscal 2026. The increase in adjusted operating expenses was driven by higher personnel-related costs and freight charges. Adjusted operating income for the first quarter of fiscal 2027 was $79.3 million, down $1.7 million, or 2.2%, compared with the first quarter of fiscal 2026. Adjusted operating margin was 23.4%, down 70 basis points when compared with the same period of fiscal 2026. The adjusted income tax rate for the first quarter of fiscal 2027 was 25.7%, up 180 basis points when compared with 24.9% in the first quarter of fiscal 2026. The increase in the effective income tax rate was primarily driven by stock compensation shortfalls.
First quarter fiscal 2027 adjusted net income was $52.3 million, up $0.9 million, or 1.8%, and adjusted earnings per diluted share was $1.14, up 3.6%, each when compared with the same period of fiscal 2026.
Financial statements
Income Statement
First Quarter Fiscal 2027 Reported (in millions)
| First Quarter Fiscal 2027 Reported | First Quarter Fiscal 2027 Reported | |
|---|---|---|
| Apheresis | 191.3 | 5.3% |
| MedSurg | 148.1 | 6.0% |
| Total net revenue | 339.4 | 5.6% |
Income Statement
First Quarter Fiscal 2027 — with the same period of fiscal 2026. Year-over-year organic revenue growth rates by business unit were as follows:
| First Quarter Fiscal 2027 – Organic | |
|---|---|
| Apheresis | 6.0% |
| MedSurg | 5.9% |
| Total net revenue | 5.9% |
Income Statement
| Three Months Ended – 6/27/2026 – (Dollars and Shares in Thousands, Except Per Share Data) | 6/28/2025 | Inc/(Dec) % | ||
|---|---|---|---|---|
| Condensed Consolidated Statements of Income (Unaudited) | Net revenues | 5.6% | ||
| Condensed Consolidated Statements of Income (Unaudited) | Cost of goods sold | 136,577 | 129,150 | 5.8% |
| Condensed Consolidated Statements of Income (Unaudited) | Gross profit | 202,803 | 192,244 | 5.5% |
| Condensed Consolidated Statements of Income (Unaudited) | Research and development | 16,200 | 16,261 | -0.4% |
| Condensed Consolidated Statements of Income (Unaudited) | Selling, general and administrative | 118,941 | 110,719 | 7.4% |
| Condensed Consolidated Statements of Income (Unaudited) | Amortization of acquired intangible assets | 10,204 | 11,392 | -10.4% |
| Condensed Consolidated Statements of Income (Unaudited) | Total Operating expenses | 145,345 | 138,372 | 5.0% |
| Condensed Consolidated Statements of Income (Unaudited) | Operating income | 57,458 | 53,872 | 6.7% |
| Condensed Consolidated Statements of Income (Unaudited) | Interest and other expense, net | -9,884 | -8,703 | 13.6% |
| Condensed Consolidated Statements of Income (Unaudited) | Income before provision for income taxes | 47,574 | 45,169 | 5.3% |
| Condensed Consolidated Statements of Income (Unaudited) | Provision for income taxes | 14,564 | 11,138 | 30.8% |
| Condensed Consolidated Statements of Income (Unaudited) | Net income | -3.0% | ||
| Condensed Consolidated Statements of Income (Unaudited) | Net income per common share assuming dilution | 2.9% | ||
| Weighted average shares outstanding | Basic | 45,361 | 48,111 | |
| Weighted average shares outstanding | Diluted | 45,704 | 48,353 | |
| Weighted average shares outstanding | Profit Margins: | Inc/(Dec) % | ||
| Weighted average shares outstanding | Gross profit | 59.8 | 59.8 | —% |
| Weighted average shares outstanding | Research and development | 4.8 | 5.1 | -0.3% |
| Weighted average shares outstanding | Selling, general and administrative | 35 | 34.4 | 0.6% |
| Weighted average shares outstanding | Operating income | 16.9 | 16.8 | 0.1% |
| Weighted average shares outstanding | Income before provision for income taxes | 14 | 14.1 | -0.1% |
| Weighted average shares outstanding | Net income | 9.7 | 10.6 | -0.9% |
Income Statement
Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the MedSurg business unit.
| Reconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited) – Three Months Ended June 27, 2026: – Gross profit | Gross profit | Reconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited) – Three Months Ended June 27, 2026: – Gross profit | Gross profit | Reconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited) – Three Months Ended June 27, 2026: – Operating expenses | Operating expenses | Reconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited) – Three Months Ended June 27, 2026: – Operating expenses | Operating expenses | Reconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited) – Three Months Ended June 27, 2026: – Operating income (loss) | Operating income (loss) | Reconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited) – Three Months Ended June 27, 2026: – Operating income (loss) | Operating income (loss) | Reconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited) – Three Months Ended June 27, 2026: – Interest and other expense | Interest and other (expense) income | Reconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited) – Three Months Ended June 27, 2026: – Interest and other expense | Interest and other (expense) income | Reconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited) – Three Months Ended June 27, 2026: – Provision (benefit) for income taxes | Provision (benefit) for income taxes | Reconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited) – Three Months Ended June 27, 2026: – Provision (benefit) for income taxes | Provision (benefit) for income taxes | Reconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited) – Three Months Ended June 27, 2026: – Net income (loss) | Net income (loss) | Reconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited) – Three Months Ended June 27, 2026: – Net income (loss) | Net income (loss) | Reconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited) – Three Months Ended June 27, 2026: – Earnings per diluted share | Earnings per diluted share | Reconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited) – Three Months Ended June 27, 2026: – Earnings per diluted share | Earnings per diluted share | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported | 202,803 | 145,345 | 57,458 | -9,884 | 14,564 | 33,010 | 0.72 | |||||||||||||||||||||
| Amortization of acquired intangible assets | -10,204 | 10,204 | 2,285 | 7,919 | 0.16 | |||||||||||||||||||||||
| Integration and transaction costs | 1,285 | -1,434 | 2,719 | -423 | 3,142 | 0.07 | ||||||||||||||||||||||
| Restructuring costs | 783 | -1,515 | 2,298 | 537 | 1,761 | 0.04 |
Balance Sheet
Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the MedSurg business unit.
| Condensed Consolidated Balance Sheets (Unaudited) – June 27, 2026 | Condensed Consolidated Balance Sheets (Unaudited) – March 28, 2026 | ||
|---|---|---|---|
| Assets | Cash and cash equivalents | 223,384 | 245,440 |
| Assets | Accounts receivable, net | 216,071 | 216,855 |
| Assets | Inventories, net | 306,739 | 306,370 |
| Assets | Other current assets | 64,638 | 66,214 |
| Assets | Total current assets | 810,832 | 834,879 |
| Assets | Property, plant & equipment, net | 303,778 | 305,761 |
| Assets | Intangible assets, net | 434,512 | 447,655 |
| Assets | Goodwill | 656,884 | 656,368 |
| Assets | Other assets | 159,394 | 151,262 |
| Assets | Total assets | 2,365,400 | 2,395,925 |
| Liabilities & Stockholders' Equity | Short-term debt & current maturities | 4,956 | 5,015 |
| Liabilities & Stockholders' Equity | Other current liabilities | 258,279 | 277,584 |
| Liabilities & Stockholders' Equity | Total current liabilities | 263,235 | 282,599 |
| Liabilities & Stockholders' Equity | Long-term debt | 1,169,202 | 1,219,565 |
| Liabilities & Stockholders' Equity | Other long-term liabilities | 95,862 | 97,441 |
| Liabilities & Stockholders' Equity | Stockholders' equity | 837,101 | 796,320 |
| Liabilities & Stockholders' Equity | Total liabilities & stockholders' equity | 2,365,400 | 2,395,925 |
Cash Flow
Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the MedSurg business unit.
| Condensed Consolidated Statements of Cash Flows (Unaudited) – Three Months Ended – June 27, 2026 | ||
|---|---|---|
| Cash Flows from Operating Activities: | Net income | 33,010 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Depreciation and amortization | 27,111 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Share-based compensation expense | 9,311 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Deferred income taxes | 668 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Change in other non-cash operating activities | 2,227 |
| Change in operating assets and liabilities: | Change in accounts receivable, net | 297 |
| Change in operating assets and liabilities: | Change in inventories, net | -1,004 |
| Change in operating assets and liabilities: | Change in prepaid income taxes | 6,101 |
| Change in operating assets and liabilities: | Change in other assets and other liabilities | -12,783 |
| Change in operating assets and liabilities: | Change in accounts payable and accrued expenses | -12,615 |
| Change in operating assets and liabilities: | Net cash provided by operating activities | 52,323 |
| Cash Flows from Investing Activities: | Capital expenditures | -7,906 |
| Cash Flows from Investing Activities: | Non-cash transfers from inventory to property, plant and equipment for Haemonetics equipment | -5,565 |
| Cash Flows from Investing Activities: | Proceeds from sale of property, plant and equipment | 237 |
| Cash Flows from Investing Activities: | Other investments | -9,000 |
| Cash Flows from Investing Activities: | Net cash used in investing activities | -22,234 |
| Cash Flows from Financing Activities: | Repayments, net of borrowings | -51,563 |
| Cash Flows from Financing Activities: | Proceeds from employee stock programs | 3,549 |